Arvin-Berod Marie, Desroches-Castan Agnès, Bonte Simon, Brugière Sabine, Couté Yohann, Guyon Laurent, Feige Jean-Jacques, Baussanne Isabelle, Demeunynck Martine
Univ. Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France.
Univ. Grenoble Alpes, Inserm, CEA, BIG-BCI, 38000, Grenoble, France.
ACS Omega. 2017 Dec 31;2(12):9221-9230. doi: 10.1021/acsomega.7b01184. Epub 2017 Dec 27.
We describe the design and optimization of polyfunctional scaffolds based on a fluorescent indolizine core derivatized with various orthogonal groups (amines, esters, oximes, alkynes, etc.). To show one application as tools in biology, the scaffold was used to prepare drug-biotin conjugates that were then immobilized onto avidin-agarose for affinity chromatography. More specifically, the antiangiogenic drug COB223, whose mechanism of action remained unclear, was chosen as a proof-of-concept drug. The drug-selective discrimination of proteins observed after elution of the cell lysates through the affinity columns, functionalized either with the biologically active COB223 or a structurally related inactive analogue (COB236), is a clear indication that the presence of the indolizine core does not limit drug-protein interaction and confirms the usefulness of the indolizine scaffold. Furthermore, the separation of COB223-interacting proteins from human placental extracts unveiled unanticipated protein targets belonging to the family of regulatory RNA-binding proteins, which opens the way to new hypotheses on the mode of action of this antiangiogenic drug.
我们描述了基于用各种正交基团(胺、酯、肟、炔烃等)衍生化的荧光中氮茚核心的多功能支架的设计和优化。为了展示其作为生物学工具的一种应用,该支架被用于制备药物 - 生物素缀合物,然后将其固定在抗生物素蛋白 - 琼脂糖上用于亲和色谱。更具体地说,选择作用机制尚不清楚的抗血管生成药物COB223作为概念验证药物。通过用生物活性COB223或结构相关的无活性类似物(COB236)功能化的亲和柱洗脱细胞裂解物后观察到的蛋白质的药物选择性区分,清楚地表明中氮茚核心的存在并不限制药物 - 蛋白质相互作用,并证实了中氮茚支架的实用性。此外,从人胎盘提取物中分离与COB223相互作用的蛋白质揭示了属于调节性RNA结合蛋白家族的意外蛋白质靶点,这为这种抗血管生成药物的作用方式开辟了新的假设途径。